Document is current
Any future updates will be listed below
-
Authors
Yan, Wenjing
Liu, Jiakun
Xie, Xuedong
Jin, Qianqian
Yang, Yue
Pan, Yi
Zhang, Yanfeng
Zhang, Fangfang
Wang, Yan
Liu, Jianxing
Jin, Liang https://orcid.org/0000-0002-4995-3553
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82373925, 82070801, 82370804, 82100858)
Natural Science Foundation of Jiangsu Province (BK20221520, BK20200569)
Higher Education Discipline Innovation Project (B16046)
Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD, 2632023TD03)
- License Information
-
More Information
Article History
Received: 26 June 2024
Accepted: 6 November 2024
First Online: 19 November 2024
Declarations
:
: hUCMSCs are provided by Jiangsu Cell Tech Medical Research Institute Co., Ltd. The product was registered and reviewed by the China Clinical Trial Center (Registration No. ChiCTR2000031494) []. All animal procedures were performed in accordance with the guidelines for the Care and Use of Laboratory Animals and the Animal Welfare Act in China and approved by the Committee of Ethics on Experimentation of China pharmaceutical University (Project title: The therapeutic effect and mechanism of human umbilical cord-derived mesenchymal stem cells on androgenetic alopecia; Approval date: 2023.06.01; Approval number: 2023-06-028). The ethical approval permits the use of human umbilical cord-derived mesenchymal stem cells for animal experiments.
: All authors confirm their consent for publication.
: The authors declare no competing interests.
